IMC-1C11 is an investigational monoclonal antibody designed to target and block the Vascular Endothelial Growth Factor Receptor (VEGFR) known as KDR, on the surface of growing endothelial cells.
Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.
Two important SUTENT targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.
Two important sunitinib malate targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are expressed by many types of solid tumors, and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.
In the treatment of renal cell carcinoma, Sutent suppresses the growth primarily by inhibiting the intracellular signal transduction related to the vascular endothelial growth factor receptor (VEGFR) and the platelet derived growth factor receptor (PDGFR).
6,811,779 from the United States Patent and Trademark Office covering the therapeutic use of a vascular endothelial growth factor receptor (VEGFR) antibody and either radiation or a chemotherapeutic agent for use in the treatment of cancer.
6,811,779 from the United States Patent and Trademark Office covering the therapeutic use of a vascular endothelial growth factor receptor (VEGFR) antibody and either radiation or a chemotherapeutic agent for use in the treatment of cancer.
Business Editors DUBLIN, Ireland--(BUSINESS WIRE)--May 6, 2004 A review of the progress in utilizing biological strategies to inhibit vascular endothelial growth factor receptor (VEGF/VEGFR) signal transduction for the treatment of cancer Research and Markets (http://www.
